Comparative Pharmacology
Head-to-head clinical analysis: DOXY SLEEP AID versus DOXYLAMINE SUCCINATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXY SLEEP AID versus DOXYLAMINE SUCCINATE.
DOXY-SLEEP-AID vs DOXYLAMINE SUCCINATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxy-Sleep-Aid is a sedative-hypnotic drug that acts as a positive allosteric modulator of GABA-A receptors, enhancing the inhibitory effects of GABA. It selectively binds to α1 subunits of GABA-A receptors, promoting sleep onset and maintenance.
Antagonist at histamine H1 receptors, producing sedative and antihistaminic effects; also possesses anticholinergic properties.
Doxylamine succinate 25 mg orally once daily at bedtime.
6.25 to 25 mg orally every 4 to 6 hours as needed, not to exceed 150 mg per day.
None Documented
None Documented
10-12 hours; extended in elderly and hepatic impairment
Terminal elimination half-life ranges from 10 to 12 hours in adults. In elderly patients, half-life may be prolonged (up to 15-18 hours) due to reduced renal clearance.
Renal: 40% unchanged; biliary/fecal: 60% as metabolites
Renal excretion of metabolites (30-60% as conjugated metabolites, <5% unchanged). Fecal elimination is minor (<10%).
Category C
Category C
Antihistamine (Sedating)
Antihistamine (Sedating)